In this manuscript, we demonstrate a personal perspective that discusses the expectations versus the real word results and outcomes of three repurposed COVID-19 drugs; tocilizumab, remdesivir and favipiravir, which resembled the well-known metaphor; the good, the bad and the ugly, respectively. We wish that this manuscript might help other colleagues to consider the risk benefit ratio before a decision is made using any of these drugs.